FluGen said its intranasal, "universal" flu vaccine helped protect trial participants against a "highly mismatched" strain.
A former deputy director of the old China FDA has been handed to the prosecutors over suspected duty-related crimes.
Here is some other vaccine news of note for the week.
Merck's 15-strain pneumococcal vaccine got an FDA breakthrough tag for children, months after Pfizer's 20-valent shot won one in adults.
Pfizer's Staphylococcus aureus vaccine candidate was among a group of pipeline shots the company hoped could propel growth beyond Prevnar 13.
Merck has been battling allegations that it illegally bundled vaccines to dissuade competition, but for now, the lawsuit may proceed.
Takeda's dengue shot met its goal in a pivotal phase 3 study that covered eight countries and more than 20,000 participants.
WuXi Biologics is forming a human vaccine-focused CDMO joint venture with local veterinary vaccine firm Shanghai Hile Bio-Technology.
